On Nov. 24, the U.S. Food and Drug Administration (FDA) approved:
- Fluad, the first seasonal influenza vaccine containing an adjuvant
- Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with metastatic squamous non-small cell lung cancer, who have not previously received medication specifically for treating their metastatic lung cancer.
